Subclinical thyroid dysfunction symptoms in older adults: cross-sectional study in UK primary care

INTRODUCTION
Subclinical thyroid dysfunction is characterised by thyroid-stimulating hormone (TSH) concentrations outside the stated reference range accompanied by free thyroxine (FT4) concentrations within the reference range.1 Thyroid function tests are commonly requested for older adults in primary care either routinely or in response to presentation of symptoms, and identify large numbers of individuals with subclinical thyroid dysfunction.2,4 The authors have previously demonstrated low levels of progression (<0.5%) of subclinical thyroid dysfunction to overt disease in older individuals over a period of up to 5 years, supporting guidelines that indicate treatment of subclinical dysfunction is not necessary to prevent progression.7 However, a better understanding of whether subclinical thyroid dysfunction itself is associated with any symptom excess, which may be amenable to intervention, is still required to guide clinical management of this condition. A previous community-based population study demonstrated symptoms to be poorly predictive of TSH,4 though other research suggests a higher prevalence of symptoms in individuals with subclinical thyroid dysfunction.3–11 However, these studies have significant limitations in their application to primary care or community-based populations being derived from endocrine clinic populations.3–11 Additionally, these data relate to middle-aged populations, and all studies have mean ages in the range 43–47 years, where the overlap of symptoms attributable to older age and thyroid dysfunction are likely to be less widespread and hence more discriminatory. Therefore, there continue to be calls for further research in subclinical thyroid dysfunction owing to poor understanding of how to best manage this condition.12,13 This study aimed to build on previous work and definitively explore whether subclinical thyroid dysfunction in older adults confers additional symptom burden, and also whether specific symptom clusters are associated with subclinical thyroid dysfunction rather than being typical of older-age presentations. Such understanding may enable reductions in the cost of repeat testing in this patient group and also advise further trial outcomes.

METHOD
Recruitment and participants
This cross-sectional survey was nested within a longitudinal study of thyroid function in an established cohort, the Birmingham Elderly Thyroid Study (BETS) cohort, of 5881 individuals living in a community setting, aged ≥65 years at initial screen, from 19 practices representative of the UK,8–10,15 GPs confirmed eligibility and suitability of follow-up protocol.

Recruitment and participants
This cross-sectional survey was nested within a longitudinal study of thyroid function in an established cohort, the Birmingham Elderly Thyroid Study (BETS) cohort, of 5881 individuals living in a community setting, aged ≥65 years at initial screen, from 19 practices representative of the UK,8–10,15 GPs confirmed eligibility and suitability of follow-up protocol.

Abstract
Background
Subclinical thyroid dysfunction — abnormal serum thyrotrophin (thyroid-stimulating hormone; TSH) concentrations with normal free thyroxine (FT4) is common in older people. It remains unclear whether individuals with subclinical serum status experience an increased symptom profile.

Aim
To compare the prevalence of those symptoms typically associated with overt thyroid dysfunction in older individuals with a subclinical and euthyroid serum profile.

Design and setting
Cross-sectional study, nested within the Birmingham Elderly Thyroid Study (BETS), from 19 UK general practices.

Method
Adults living in a community setting (aged ≥65 years), without overt thyroid dysfunction or associated treatment, self-reported the presence or absence of 18 symptoms (while serum result naïve). Serum concentrations of TSH and FT4 were measured to establish thyroid status.

Results
A total of 2870 individuals were screened: 2703 (94%) were categorised as euthyroid (normal), 94 (3%) subclinically hypothyroid, and 53 (2%) subclinically hyperthyroid. Symptoms were common in all groups. No significant differences in the prevalence of individual symptoms were observed between the euthyroid and subclinically hypothyroid groups nor in comparison with the subclinically hyperthyroid group. Multivariate logistic regression analysis failed to reveal an association between individual or multiple symptoms and subclinical status.

Conclusion
Findings suggest that subclinical thyroid dysfunction does not confer a symptom burden in older individuals and support adherence to guidelines in the non-treatment of subclinical thyroid dysfunction. GPs may use the findings to reassure older people presenting with symptoms that subclinical thyroid dysfunction is an unlikely explanation. The presence of persistently abnormal TSH concentrations may be linked to long-term risks of cardiovascular disease, especially atrial fibrillation, but whether this should prompt treatment and whether such treatment alters vascular outcomes is unknown.

Keywords
 ageing, primary health care; subclinical thyroid dysfunction; symptoms; thyroid function tests.
Eligible participants received a postal invitation letter, reply slip, and freepost envelope addressed to the research office. Patients interested in participating were sent a symptoms questionnaire with a request to complete it before attending the research clinic for venepuncture. At the clinic, consent was obtained and a blood sample for thyroid function testing acquired. Samples were collected in plastic vacuette 4 ml serum separator clot activator tubes. Research clinics were conducted over a period of 19 months with symptom details being provided concurrent to individual patient appointments.

### Evaluation of symptoms

Participants self-reported the presence or absence of 18 classic symptoms of overt hypo- and hyperthyroidism by questionnaire. The questionnaire was a supplemented version of the Colorado Hypothyroid Symptom survey, a validated questionnaire for assessment of symptoms of thyroid hormone deficiency.\(^7\) The format of the original survey was preserved; however, six hyperthyroid symptoms identified from the literature were added.\(^8\) The final questionnaire comprised: six hyperthyroid symptoms (excessive perspiration, tremor, frequent palpitation, sensitivity to heat, fast thinking, weight loss), nine hypothyroid symptoms (hoarse voice, deep tone of voice, dry skin, puffy eyes, muscle cramps, constipation, sensitivity to cold, slow thinking, and weight gain) and three symptoms (poor memory, weak muscles, and lethargy) that can be associated with both hyper- and hypothyroidism.

The questionnaire was piloted by 10 volunteers aged ≥65 years to assess user understanding and experience. Refinements were made based on the feedback obtained.

### Thyroid function testing

Thyroid function testing was performed by the Regional Endocrine Laboratory at University Hospital Birmingham, National Health Service Foundation Trust (UHB). Serum TSH and FT4 concentrations were determined for all individuals. If a serum TSH concentration above or below the limits of the reference range was identified, serum free tri-iodothyronine (FT3) was also measured. Serum TSH, FT4, and FT3 concentrations were measured by electrochemiluminescent immunoassays using the Roche E170 (Roche Diagnostics, Burgess Hill, UK). The TSH assay was calibrated against the second international reference preparation 80/558. The associated inter-assay coefficient of variation for TSH was 1.5% (range 0.5–33.0 mIU/L), FT4 2.0–2.5% (9.0–66.0 pmol/L), and FT3 2.0–3.5% (4.0–21.0 pmol/L). The lower limit of reporting for the TSH assay was 0.02 mIU/L and the manufacturer’s quoted mean functional sensitivity was 0.014 mIU/L. Algorithms relating to current local clinical practice and laboratory reference criteria were used to classify thyroid status (Table 1).

### Demographic and lifestyle data

Age and deprivation score were calculated from the participants’ date of birth and postcode, respectively. The Index of Multiple Deprivation 2004 (IMD) was used as a proxy measure of socioeconomic status with higher IMD scores indicating greater deprivation.\(^9\) Primary care medical records were reviewed to collect data on medical history and concomitant prescription

---

**How this fits in**

Subclinical thyroid dysfunction is a biochemical diagnosis that is common in older age. Though older patients with this diagnosis may report symptoms like those found in overt thyroid dysfunction, it is unknown whether subclinical thyroid dysfunction itself is associated with symptom excess. This large population-based survey demonstrates that subclinical thyroid dysfunction in the older population does not confer additional symptom burden. Findings support current guidance for not treating subclinical thyroid dysfunction in older individuals and provide an evidence base for GPs to use in discussion with patients experiencing symptoms who have mildly abnormal thyroid function test results.

---

**Table 1. Classification of thyroid status based on TSH and FT4 concentration**

<table>
<thead>
<tr>
<th>Thyroid status</th>
<th>Serum thyrotrophin (TSH) mIU/L</th>
<th>Serum thyroxine (FT4) pmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overt hyperthyroidism</td>
<td>&lt;0.3</td>
<td>&gt;10</td>
</tr>
<tr>
<td>Subclinical hyperthyroid</td>
<td>&lt;0.3</td>
<td>10–22</td>
</tr>
<tr>
<td>Euthyroid</td>
<td>0.3–4.5</td>
<td>10–22</td>
</tr>
<tr>
<td>Subclinical hypothyroid</td>
<td>&gt;4.5</td>
<td>10–22</td>
</tr>
<tr>
<td>Overt hypothyroidism</td>
<td>&gt;4.5</td>
<td>&lt;22</td>
</tr>
</tbody>
</table>

FT4 = free thyroxine. TSH = thyroid-stimulating hormone.
medication pre-specified as likely to be associated with category of thyroid function, with reported symptoms, or to interfere with tests of thyroid function. Participants self-reported smoking status.

**Statistical analysis**

T-tests and χ² tests were used to compare the participants with subclinical hypo- and hyperthyroidism with euthyroid participants with respect to patient characteristics, for example, demographics, medical history, concomitant disease, and prescription medication. Univariate logistic regression techniques were used to establish unadjusted odds ratios representing the odds of subclinical hypo- or hyperthyroidism in participants reporting presence of individual symptoms, divided by the odds of subclinical hypo- or hyperthyroidism in participants reporting absence of the symptom.

Multivariate logistic regression analysis was then undertaken to further examine the relationship between individual symptoms and thyroid function category, and establish the likelihood of subclinical thyroid dysfunction after controlling for the effects of the covariates: age, sex, deprivation score, smoking status, concomitant disease, and prescription medication. To enable further exploration of the relationship between category of thyroid function and presence of multiple symptoms, uni- and multivariate logistic regression was undertaken to establish the change in odds of a subclinical hypo- or hyperthyroid result as the total number of symptoms reported increased, with and without all other factors being equal.

**RESULTS**

A total of 4447 individuals were invited to participate in the follow-up screening study (Figure 1). Participants were excluded from the original cohort (n = 5881) if during the 5-year interval period they had died (n = 501), deregistered from participating practice (n = 53), newly treated for thyroid disease (n = 53), had missing a symptoms questionnaire (n = 7), had missing thyroid function test (n = 6), or had full screen (n = 2870).

**Figure 1. Study flow diagram.**

![Figure 1. Study flow diagram.](image_url)

**Table 2. Prevalence of hypothyroid symptoms and risk factors for subclinical hypothyroidism**

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Euthyroid, % (95% CI)a</th>
<th>Subclinical hypothyroidism, % (95% CI)b</th>
<th>Unadjusted OR (95% CI)</th>
<th>P-value</th>
<th>Adjusted OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nine symptoms typically associated with overt hypo/hyperthyroidism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hoarse voice</td>
<td>6.0 (5.2 to 7.0)</td>
<td>8.0 (4.5 to 13.8)</td>
<td>1.3 (0.7 to 2.6)</td>
<td>0.35</td>
<td>1.4 (0.7 to 2.8)</td>
<td>0.24</td>
</tr>
<tr>
<td>Deep tone of voice</td>
<td>6.4 (5.5 to 7.4)</td>
<td>9.5 (5.6 to 15.6)</td>
<td>1.5 (0.9 to 2.8)</td>
<td>0.15</td>
<td>1.5 (0.8 to 2.7)</td>
<td>0.23</td>
</tr>
<tr>
<td>Dry skin</td>
<td>32.2 (30.4 to 34.0)</td>
<td>33.3 (26.0 to 41.6)</td>
<td>1.1 (0.7 to 1.5)</td>
<td>0.79</td>
<td>1.0 (0.7 to 1.5)</td>
<td>0.87</td>
</tr>
<tr>
<td>Puffy eyes</td>
<td>13.3 (12.1 to 14.7)</td>
<td>15.9 (10.8 to 23.0)</td>
<td>1.2 (0.8 to 2.0)</td>
<td>0.38</td>
<td>1.2 (0.7 to 1.9)</td>
<td>0.48</td>
</tr>
<tr>
<td>Muscle cramps</td>
<td>15.1 (13.8 to 16.5)</td>
<td>15.2 (10.2 to 22.1)</td>
<td>1.0 (0.6 to 1.6)</td>
<td>0.97</td>
<td>0.9 (0.6 to 1.5)</td>
<td>0.80</td>
</tr>
<tr>
<td>Constipation</td>
<td>13.2 (11.9 to 14.5)</td>
<td>14.5 (9.6 to 21.3)</td>
<td>1.1 (0.7 to 1.8)</td>
<td>0.65</td>
<td>1.0 (0.6 to 1.7)</td>
<td>0.99</td>
</tr>
<tr>
<td>Sensitivity to cold</td>
<td>34.8 (33.0 to 36.7)</td>
<td>37.2 (29.6 to 45.6)</td>
<td>1.1 (0.8 to 1.6)</td>
<td>0.56</td>
<td>1.1 (0.8 to 1.6)</td>
<td>0.64</td>
</tr>
<tr>
<td>Slow thinking</td>
<td>7.9 (6.9 to 8.9)</td>
<td>11.6 (7.3 to 18.9)</td>
<td>1.5 (0.9 to 2.6)</td>
<td>0.12</td>
<td>1.5 (0.9 to 2.7)</td>
<td>0.13</td>
</tr>
<tr>
<td>Weight gain</td>
<td>48.5 (46.7 to 50.4)</td>
<td>53.6 (45.3 to 61.7)</td>
<td>1.2 (0.9 to 1.7)</td>
<td>0.24</td>
<td>1.2 (0.9 to 1.8)</td>
<td>0.25</td>
</tr>
<tr>
<td>Three symptoms that can be associated with overt hyper-/hypothyroidism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poor memory</td>
<td>9.7 (8.6 to 10.9)</td>
<td>8.0 (4.5 to 13.7)</td>
<td>0.8 (0.4 to 1.5)</td>
<td>0.50</td>
<td>0.8 (0.4 to 1.6)</td>
<td>0.56</td>
</tr>
<tr>
<td>Weak muscles</td>
<td>14.3 (13.0 to 15.7)</td>
<td>14.5 (9.6 to 21.3)</td>
<td>1.0 (0.6 to 1.7)</td>
<td>0.95</td>
<td>1.0 (0.6 to 1.7)</td>
<td>0.90</td>
</tr>
<tr>
<td>Lethargy</td>
<td>14.6 (15.0 to 17.8)</td>
<td>10.9 (6.7 to 17.3)</td>
<td>0.6 (0.4 to 1.1)</td>
<td>0.10</td>
<td>0.6 (0.4 to 1.1)</td>
<td>0.12</td>
</tr>
<tr>
<td>Multiple symptoms</td>
<td>Total number of symptoms reported</td>
<td>Median (IQR) 2.0 (2.0)</td>
<td>Median (IQR) 2.0 (2.0)</td>
<td>1.0 (0.95 to 1.1)</td>
<td>0.33</td>
<td>1.0 (0.9 to 1.1)</td>
</tr>
</tbody>
</table>

*aUnless otherwise stated*  
*bAdjusted odds of subclinical hypothyroidism after controlling for sociodemographic factors (age, sex, deprivation score, smoking status), concomitant disease, and prescription medication. Bonferroni adjusted α value to control for type 1 error resulting from multiple comparisons = 0.004. IQR = interquartile range. OR = odds ratio.
Description of the subgroups
A total of 2703 participants (94%, N = 2870) were classified as euthyroid, 138 (5%) as subclinically hypothyroid, and 29 (1%) subclinically hyperthyroid. The euthyroid group were slightly younger than the subclinically hyperthyroid group (mean age 76.8 years versus 79.1 years respectively, P = 0.02) and the subclinically hypothyroid group (mean age 76.8 years versus 77.7 years respectively, P = 0.05). The three groups were similar with respect to sex and deprivation score. A significantly higher proportion of the euthyroid group compared with the subclinically hypothyroid group had a previous diagnosis of pulmonary disease (12.9% versus 3.6%, P = 0.03) but there were no statistically significant differences between the euthyroid and subclinical groups with respect to any other concomitant disease or prescription medication (data not shown).

Symptom expression and subclinical hypothyroidism
There were no significant differences between the euthyroid and subclinical hypothyroid groups with respect to presence of individual or multiple hypothyroid symptoms (Table 2). Unadjusted and adjusted odds ratios representing the odds of subclinically hypothyroid status in participants reporting symptom presence, divided by the odds of subclinical status in participants reporting thyroid function test results or missing symptom data (n = 13), and newly identified treatment for thyroid dysfunction (n = 53).

Table 3. Prevalence of hyperthyroid symptoms and risk factors for subclinical hyperthyroidism

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Euthyroid, % (95% CI)</th>
<th>Subclinical hypothyroidism, % (95% CI)</th>
<th>Unadjusted OR (95% CI)</th>
<th>P-value</th>
<th>Adjusted OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Six symptoms typically associated with hyperthyroidism</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excessive perspiration</td>
<td>3.1 (2.5 to 3.8)</td>
<td>3.4 (0.6 to 17.2)</td>
<td>1.1 (0.2 to 8.3)</td>
<td>0.92</td>
<td>1.4 (0.2 to 10.9)</td>
<td>0.73</td>
</tr>
<tr>
<td>Tremor</td>
<td>4.3 (3.6 to 5.1)</td>
<td>3.4 (0.6 to 17.2)</td>
<td>0.8 (0.1 to 6.0)</td>
<td>0.83</td>
<td>0.6 (0.8 to 5.0)</td>
<td>0.66</td>
</tr>
<tr>
<td>Frequent palpitation</td>
<td>6.0 (5.2 to 7.0)</td>
<td>6.9 (1.9 to 22.0)</td>
<td>1.2 (0.3 to 4.9)</td>
<td>0.85</td>
<td>1.3 (0.3 to 5.9)</td>
<td>0.72</td>
</tr>
<tr>
<td>Sensitivity to heat</td>
<td>10.7 (9.6 to 11.9)</td>
<td>13.8 (5.5 to 30.4)</td>
<td>1.3 (0.5 to 3.9)</td>
<td>0.59</td>
<td>1.6 (0.5 to 4.7)</td>
<td>0.42</td>
</tr>
<tr>
<td>Fast thinking</td>
<td>22.7 (21.1 to 24.3)</td>
<td>31.0 (17.3 to 49.2)</td>
<td>1.5 (0.7 to 3.4)</td>
<td>0.29</td>
<td>1.4 (0.6 to 3.2)</td>
<td>0.42</td>
</tr>
<tr>
<td>Weight loss</td>
<td>7.4 (7.0 to 9.1)</td>
<td>3.4 (0.6 to 17.2)</td>
<td>0.4 (0.1 to 3.3)</td>
<td>0.43</td>
<td>0.4 (0.05 to 2.8)</td>
<td>0.33</td>
</tr>
</tbody>
</table>

| **Three symptoms that can be associated with overt hyper- or hypothyroidism** |                        |                                        |                         |         |                      |         |
| Poor memory                                        | 9.7 (8.6 to 10.9)      | 0                                      | 0.4 (0.1 to 1.9)        | 0.27    | 0.4 (0.1 to 1.9)     | 0.27    |
| Weak muscles                                       | 14.3 (13.0 to 15.7)    | 6.9 (1.9 to 22.0)                      | 0.6 (0.2 to 2.0)        | 0.39    | 0.6 (0.2 to 2.0)     | 0.41    |
| Lethargy                                           | 16.4 (15.0 to 17.8)    | 10.3 (3.6 to 26.4)                     | 0.6 (0.2 to 2.0)        | 0.41    |                      |         |

| **Multiple symptoms**                              | Median (IQR)           | Median (IQR)                           | 0.9 (0.6 to 1.3)        | 0.44    | 0.8 (0.6 to 1.3)     | 0.41    |

*Unless otherwise stated. Adjusted odds of subclinical hyperthyroidism after controlling for sociodemographic factors [age, sex, deprivation score, smoking status], concomitant disease, and prescription medication. Bonferroni adjusted α value to control for type I error resulting from multiple comparisons = 0.005. IQR = interquartile range. OR = odds ratio.
symptom absence, are reported. Visual exploration of the distribution of total number of symptoms reported by the euthyroid and subclinical hypothyroid groups did not demonstrate a clear relationship between multiple symptoms and thyroid function category (Figure 2).

Symptom expression and subclinical hyperthyroidism
For completeness, the prevalence of individual symptoms and total number of symptoms reported in the euthyroid and subclinical hyperthyroid groups are reported in Table 3, though it is acknowledged that a low number of identified subclinically hyperthyroid cases restricts interpretation. No significant differences between the groups were observed with respect to presence of any individual hyperthyroid symptom or total number of symptoms reported. Visual exploration of the distribution of total number of symptoms reported by the groups also failed to demonstrate a clear relationship between total number of symptoms reported and thyroid function category (Figure 3).

DISCUSSION
Summary
This population survey suggests that symptoms commonly associated with overt thyroid dysfunction are relatively prevalent in older individuals living in a community; however, This study did not demonstrate a greater prevalence of any established symptoms in those with subclinical thyroid dysfunction compared with euthyroid controls. Furthermore, presence of multiple symptoms were not associated with subclinical thyroid dysfunction.

Strengths and limitations
The strengths of this study are the large number of unselected older individuals investigated and the simultaneous and detailed evaluation of thyroid function, self-reported symptoms, concomitant disease, and prescription medication. Evidence-based development of the symptom questionnaire was employed to ensure that the most relevant and sensitive symptoms, reflecting a variety of metabolic processes and involving a range of organ systems, were selected and captured. Furthermore, all participants completed the questionnaire before thyroid function testing so that their responses were not influenced by knowledge of their thyroid status.

This study did not evaluate other clinical effects, such as altered cardiac morphology, which may be attributed to subclinical thyroid dysfunction. Further evidence in such impacts is needed in relation to unselected populations to fully determine any consequence of living with marginally altered TSH or FT4.

Comparison with existing literature
This study failed to identify symptoms that alone, or in combination, are associated with subclinical thyroid dysfunction in older individuals. This contrasts with previous studies,9–11 which identified an increased symptom burden, but whose findings are likely to be influenced by the recruitment from secondary care endocrine settings and smaller cohorts.

It is also noted that direct comparison with these studies is not supported by the much younger populations recruited, with the study presented here being the first significant screening study to explore symptom profiles in an older cohort, that is, the general population who are most likely to receive thyroid function testing and be identified with subclinical thyroid states.

These findings support those of a smaller retrospective case-note study conducted in a primary care geriatric service that found no significant difference in the frequencies of any signs or symptoms associated with hypothyroidism between subclinical and euthyroid individuals.21

Implications for research and practice
Overall findings suggest that subclinical thyroid dysfunction does not confer a symptom burden in older individuals living...
in a community. This lack of association further supports adherence to guidelines in the non-treatment of subclinical thyroid dysfunction and provides an evidence base for GPs to use in discussion of symptoms and associated likelihood of subclinical dysfunction explaining these in their older patients.

In older individuals the diagnosis of subclinical thyroid dysfunction should be based on laboratory results indicating persistently (over a period of 3–6 months to effectively exclude acute non-thyroidal and drug-related causes) abnormal TSH levels alongside FT4 levels within reference range.22

In terms of management of subclinical thyroid dysfunction, the findings of a recent meta-analysis and systematic review incorporating data from 21 trials does not support the routine use of thyroid hormone therapy in adults with subclinical hypothyroidism. Results of this review consistently demonstrated no association of therapy with improved outcomes.23

The evidence to guide management of subclinical hyperthyroidism remains inconclusive with few interventional studies showing benefit in clinically important outcomes. Since epidemiological data demonstrate an increased rate of atrial fibrillation, heart failure, and coronary heart disease with subclinical hyperthyroidism, current European Thyroid Association guidelines recommend that treatment of subclinical hyperthyroidism be considered in older patients with cardiovascular disease, diabetes, and renal failure to avoid longer-term risks.15,24,25 National Institute for Health and Care Excellence guidelines on the assessment and management of thyroid disease were published in November 2019.16

Considering this evidence, in the presence of persistently low levels of TSH (especially levels <0.1 mIU/L) alongside pre-existing cardiovascular disease and increased cardiovascular risk factors, GPs may want to discuss, with their patients, the possible long-term risks of subclinical hyperthyroidism in order to determine whether to intervene or abstain from treatment; however, such discussions will be limited by uncertainty on whether this association is clinically significant and the lack of any evidence on the effectiveness of treatment for reducing any risks associated with subclinical hyperthyroidism. Treatment of all grades of hyperthyroidism should most appropriately be instituted by endocrine specialists.27

Further large-scale, longitudinal research is required to establish the clinical significance of the aetiology of subclinical hyperthyroidism and the impact of treatment on cardiovascular endpoints to guide management strategies.

Funding
This study was funded by the National Institute for Health Research [NIHR] via the National School for Primary Care Research. Deborah McCahon was also supported via funding from the Primary Care Research Trust [PCRT] and the Midland Research Practices Consortium [MidReC]. FD Richard Hobbs acknowledges his part-funding from the NIHR School for Primary Care Research, the NIHR Collaboration for Leadership in Health Research and Care (CLARHC) Oxford, the NIHR Oxford Biomedical Research Centre [BRC UHT], and the NIHR Oxford Medtech and In-Vitro Diagnostics Co-operative [MIC]. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

Ethical approval
Ethical approval for the study was obtained from the North Staffordshire Local Research Ethics Committee (reference number: 07/H1204/136; approval date: 19 December 2007) before commencement of the research.

Provenance
Freely submitted; externally peer reviewed.

Competing interests
The authors have declared no competing interests.

Contributors
Deborah McCahon and Lesley Roberts contributed equally to the authorship of this paper.

Acknowledgements
The authors would like to thank the participants and GPs, the general practice staff that facilitated collection of data, Peter Lewis, Penelope Clark, and the staff at the Regional Endocrine Laboratory who conducted the thyroid function testing. The co-investigators for BETS I and/or BETS II were Sue Wilson, Jayne Franklyn, Michael Gammage, Roger Holder, Andrea Reaife, and Helen Pattison.

Discuss this article
Contribute and read comments about this article: bjp.org/letters
REFERENCES


